First one in the bag. The European Medicines Agency has accepted Alvotech’s marketing authorization application for its AVT03, a denosumab rival to Amgen’s Prolia/Xgeva brands, for review.
“EMA acceptance marks an important step towards making AVT03 available to patients and caregivers in Europe,” said Alvotech’s chief scientific officer Joseph McClellan.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?